Rong Le

Array ( [id] => 8253225 [patent_doc_number] => 20120157545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-21 [patent_title] => 'METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 13/300021 [patent_app_country] => US [patent_app_date] => 2011-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 27993 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0157/20120157545.pdf [firstpage_image] =>[orig_patent_app_number] => 13300021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9016348 [patent_doc_number] => 20130231312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-05 [patent_title] => 'TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS' [patent_app_type] => utility [patent_app_number] => 13/885638 [patent_app_country] => US [patent_app_date] => 2011-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10799 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13885638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7784809 [patent_doc_number] => 20120046365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-23 [patent_title] => 'Method and Composition for Administering an NMDA Receptor Antagonist to a Subject' [patent_app_type] => utility [patent_app_number] => 13/284630 [patent_app_country] => US [patent_app_date] => 2011-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15587 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0046/20120046365.pdf [firstpage_image] =>[orig_patent_app_number] => 13284630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12112748 [patent_doc_number] => 09868728 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-16 [patent_title] => 'Quinazoline derivatives, compositions, and uses related thereto' [patent_app_type] => utility [patent_app_number] => 13/876869 [patent_app_country] => US [patent_app_date] => 2011-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 35340 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13876869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9004474 [patent_doc_number] => 20130225599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS' [patent_app_type] => utility [patent_app_number] => 13/881548 [patent_app_country] => US [patent_app_date] => 2011-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13366 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13881548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9817943 [patent_doc_number] => 08927730 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-06 [patent_title] => 'Intramolecular hydrogen-bonded nitric oxide synthase inhibitors' [patent_app_type] => utility [patent_app_number] => 13/250554 [patent_app_country] => US [patent_app_date] => 2011-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 7086 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13250554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8904861 [patent_doc_number] => 20130172364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-04 [patent_title] => 'PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE' [patent_app_type] => utility [patent_app_number] => 13/823001 [patent_app_country] => US [patent_app_date] => 2011-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6816 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13823001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8951251 [patent_doc_number] => 20130197032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-01 [patent_title] => 'PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/823435 [patent_app_country] => US [patent_app_date] => 2011-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 19950 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 26 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13823435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8253138 [patent_doc_number] => 20120157458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-21 [patent_title] => 'IMIDAZOTRIAZINONE COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 13/237795 [patent_app_country] => US [patent_app_date] => 2011-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62986 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0157/20120157458.pdf [firstpage_image] =>[orig_patent_app_number] => 13237795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10096885 [patent_doc_number] => 09133186 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-15 [patent_title] => 'Hetero ring-fused imidazole derivative having AMPK activating effect' [patent_app_type] => utility [patent_app_number] => 13/822189 [patent_app_country] => US [patent_app_date] => 2011-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51399 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13822189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9469070 [patent_doc_number] => 08722701 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-13 [patent_title] => '1,2,3,4,5 6,7,8-octohydro-9-phenylacetamidoacridine, the preparation method and medical use thereof' [patent_app_type] => utility [patent_app_number] => 13/700395 [patent_app_country] => US [patent_app_date] => 2011-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5145 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13700395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7669022 [patent_doc_number] => 20110318291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-29 [patent_title] => 'Trehalose-containing topical drying composition and method of using same' [patent_app_type] => utility [patent_app_number] => 13/199543 [patent_app_country] => US [patent_app_date] => 2011-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2453 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13199543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8685151 [patent_doc_number] => 20130053435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-28 [patent_title] => 'Methods of Treating Alcohol Intoxication, Alcohol Use Disorders and Alcohol Abuse Which Comprises the Administration of Dihydromyricetin' [patent_app_type] => utility [patent_app_number] => 13/520727 [patent_app_country] => US [patent_app_date] => 2011-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14480 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13520727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9844362 [patent_doc_number] => 08946279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-03 [patent_title] => 'Fused ring compound for use as mineralocorticoid receptor antagonist' [patent_app_type] => utility [patent_app_number] => 13/817462 [patent_app_country] => US [patent_app_date] => 2011-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20343 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13817462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9034933 [patent_doc_number] => 20130237571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-12 [patent_title] => 'AGONISTS OF GPR40' [patent_app_type] => utility [patent_app_number] => 13/811825 [patent_app_country] => US [patent_app_date] => 2011-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72973 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13811825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7501842 [patent_doc_number] => 20110263637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'UP TO SIX WEEKS DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD' [patent_app_type] => utility [patent_app_number] => 13/184579 [patent_app_country] => US [patent_app_date] => 2011-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 111 [patent_figures_cnt] => 111 [patent_no_of_words] => 79282 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0263/20110263637.pdf [firstpage_image] =>[orig_patent_app_number] => 13184579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7501838 [patent_doc_number] => 20110263636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => '3 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD' [patent_app_type] => utility [patent_app_number] => 13/184556 [patent_app_country] => US [patent_app_date] => 2011-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 111 [patent_figures_cnt] => 111 [patent_no_of_words] => 79201 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0263/20110263636.pdf [firstpage_image] =>[orig_patent_app_number] => 13184556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7561829 [patent_doc_number] => 20110275662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-10 [patent_title] => 'METHODS OF IMPROVING SKIN QUALITY' [patent_app_type] => utility [patent_app_number] => 13/183174 [patent_app_country] => US [patent_app_date] => 2011-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6535 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20110275662.pdf [firstpage_image] =>[orig_patent_app_number] => 13183174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7501832 [patent_doc_number] => 20110263635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'METHOD OF TREATING ACTINIC KERATOSIS WITH 3.75% IMIQUIMOD CREAM' [patent_app_type] => utility [patent_app_number] => 13/182433 [patent_app_country] => US [patent_app_date] => 2011-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 111 [patent_figures_cnt] => 111 [patent_no_of_words] => 79074 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0263/20110263635.pdf [firstpage_image] =>[orig_patent_app_number] => 13182433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7501832 [patent_doc_number] => 20110263635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'METHOD OF TREATING ACTINIC KERATOSIS WITH 3.75% IMIQUIMOD CREAM' [patent_app_type] => utility [patent_app_number] => 13/182433 [patent_app_country] => US [patent_app_date] => 2011-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 111 [patent_figures_cnt] => 111 [patent_no_of_words] => 79074 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0263/20110263635.pdf [firstpage_image] =>[orig_patent_app_number] => 13182433 [rel_patent_id] =>[rel_patent_doc_number] =>)